August 2, 2021 -- Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding agents for four immuno-oncology targets.
Under terms of the deal, Autolus will be eligible to receive payment for each target Moderna licenses, as well as to receive milestone payments for each target that is successfully brought to market. Autolus will also receive royalties on net sales of each target.